News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
In August 2026, Riot Platforms reported second-quarter 2026 results showing revenue of US$174.24 million but a net loss of US$237.17 million, driven in part by almost US$27.97 million of impairment charges, while bitcoin production rose to 1,587 coins. On the same day, the company …
Sharemaestro market context Trend signal active 52 weeks +32.3%Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer - Alan BashChief Financial Officer - Carlos SantosInterim Head of R&D - Yuhong QiuDirector of Investor Relations - Caroline LeCates Paul TAKEAWAYS Worldwide Net …
Fortress Biotech (NASDAQ: FBIO) is set to release its Q2 earnings report on August 12, 2026, with analysts forecasting an EPS of -$0.20 and revenue of $18.3 million. The stock is currently deemed 125.0% overvalued by GuruFocus' GF Value™ metric, trading at $2.61 against …
This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …
Arcutis Biotherapeutics (ARQT) insider Patrick Burnett has filed a Form 144 to sell 15,000 shares of common stock through Merrill Lynch on or after August 11, 2026. These shares were acquired via a stock option exercise on January 12, 2024. Burnett previously sold 955 …
Bolt Biotherapeutics Inc. (BOLT) reported a second-quarter loss of $7.7 million, or $4.57 per share. The company generated $5,000 in revenue during the period. Bolt Biotherapeutics shares closed at $4.02 on Tuesday, down from $5.63 a year ago.
Bolt Biotherapeutics (BOLT) reported Q2 2026 financial results with collaboration revenue of $5 thousand and a net loss of $7.7 million, noting reduced R&D and G&A expenses. The company's lead ISAC candidate, BDC-4182, is progressing in a Phase 1/2 trial for gastric and gastroesophageal …
Bolt Biotherapeutics, Inc. reported minimal revenue of $5K for Q2 2026, a sharp decline from the previous year, with a net loss of $(7.72M) and diluted EPS of $(4.57). The company's revenue drop was attributed to reduced collaboration activity, while cost reductions slightly narrowed …
Riot Platforms, Inc. (RIOT) reported a Q2 loss of $0.68 per share, missing the Zacks Consensus Estimate of a $0.39 loss, but exceeded revenue expectations with $174.24 million. Despite outperforming the market year-to-date, the company currently holds a Zacks Rank #5 (Strong Sell) due …
Sharemaestro market context Trend signal active 52 weeks +32.3%Lakefront Biotherapeutics (NASDAQ:LKFT) has received an average "Hold" rating from analysts, with a consensus 12-month price target of $34.33. The company recently surpassed earnings expectations, reporting an EPS of $0.04 against an anticipated loss of $0.97, and revenue of $15.47 million, significantly higher than …
This article first appeared on GuruFocus. Total Revenue: Increased 52% year over year, driven by continued CARVYKTI demand and commercial expansion. CARVYKTI Net Trade Sales: Approximately $657 million worldwide, representing 50% year-over-year growth and 10% sequential growth. U.S. CARVYKTI Sales: Increased 32% year over …
PDS Biotechnology Corporation's stock crashed by approximately 67% after the company announced a strategic refocus of its resources towards the PDS0301 program for metastatic colorectal cancer. This shift is based on encouraging clinical data and a belief that PDS0301 offers a more attractive path …
Quick Read MSFT and AMGN offer confirmed dividends of $0.91 and $2.52 per share, with buy deadlines of August 19 and 20 to qualify for payment. Cheesecake Factory's ex-date already passed and Walmart has no confirmed next ex-date, cutting both from the eligible list. …
Sharemaestro market context Trend signal active 52 weeks +23.4% · Next-week setup negative 26.7%Legend Biotech (NASDAQ:LEGN) surged 6% after reporting its first-ever profitable quarter in Q2 2026, with revenue of $387.5 million beating estimates and adjusted EPS of $0.16 doubling consensus. The strong performance was driven by CARVYKTI net sales reaching $657 million, up 50% year-over-year, and …
Bernstein analysts raised their price target for Riot Platforms to $35, maintaining an Outperform rating, following the company's $9.1 billion data center agreement with an AI lab, reportedly Anthropic. This deal is projected to generate significant annual recurring revenue and net operating income, signaling …
Riot Platforms has signed a 20-year lease agreement worth $9 billion with Anthropic in Milam County, Texas, at the former Alcoa Corp. site. This deal could extend to $16.1 billion if two five-year extensions are exercised. The location is attracting big tech companies due …
Riot Platforms, the Bitcoin miner-turned-data center operator, has struck a $9.1 billion compute supply deal with Anthropic, a source tells Barron’s. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +32.3%PDS Biotech has scheduled the release of its quarterly financial results for the quarter ending June 30, 2026, on August 13, 2026. This announcement was initially published by PDS Biotechnology Corporation via GlobeNewswire. The news brief was created by Public Technologies (PUBT) using generative …
Riot Platforms Inc (NASDAQ:RIOT) shares rose about 4% on Tuesday after the bitcoin mining company announced a 20-year data center lease with a leading frontier AI lab in a deal valued at approximately $9.1 billion over its initial term. The tenant was not identified …
Sharemaestro market context Trend signal active 52 weeks +32.3%Riot Platforms, Inc. RIOT used its Q2 earnings call to frame 2026 around data center execution, led by a new 191-megawatt Rockdale lease with a leading frontier AI lab and a full-site Corsicana letter of intent. Financially, RIOT posted a loss of 68 cents …
Sharemaestro market context Trend signal active 52 weeks +32.3%Legend Biotech Corporation (LEGN) reported strong financial results for Q2, with revenues reaching $387.5 million, significantly surpassing the FactSet estimate of $356.0 million. This earnings flash highlights the company's robust revenue performance for the quarter.
Riot Platforms, the Bitcoin miner-turned-data center operator, has struck a $9.1 billion compute supply deal with Anthropic, a source tells Barron’s. Continue Reading
Iovance Biotherapeutics (IOVA) is gaining investor attention after reporting improved Q2 2026 results, including higher revenue and a narrower net loss, while reaffirming full-year revenue guidance of US$350-370 million. Despite a recent share price surge and a narrative suggesting it's undervalued at $18 compared …
What happened: Riot Platforms (RIOT) stock surged 17% in pre-market trading on Tuesday. What's behind the move: The bitcoin mining company, which has pivoted toward selling data center capacity, signed a deal with a major AI developer, widely reported to be Anthropic, in a …
Sharemaestro market context Trend signal active 52 weeks +32.3%Riot Platforms, the Bitcoin miner-turned-data center operator, has struck a $9.1 billion compute supply deal with Anthropic, a source tells Barron’s. Continue Reading
Key Points Interested in Legend Biotech Corporation Sponsored ADR? Here are five stocks we like better. CARVYKTI sales rose sharply: Worldwide net trade sales increased 50% year over year to approximately $657 million, driven by earlier-line treatment adoption in the U.S. and international expansion …
Search by ticker symbol or company name and select a result to open its chart.